Erman Akkus, MD, discusses why second-line treatment in advanced hepatocellular carcinoma remains undefined and how reconstructed patient data can help fill it.
Erman Akkus, MD
Advertisement
Articles by Erman Akkus, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma
4
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
5